Key Highlights

  • Net loss narrowed to USD 7.1 million from USD 7.8 million a year earlier.
  • The loss was USD 0.90 per share versus USD 4.21 a year earlier.
  • Research and development expense fell to USD 3.9 million from USD 5.6 million.
  • Cash was USD 5.1 million at September 30, 2026.

Loss Narrows as Research Spending Eases

Modular Medical, Inc. (NASDAQ:MODD) reported a fiscal second-quarter net loss of USD 7,103 thousand versus USD 7,790 thousand, or USD 0.90 per share versus USD 4.21. Weighted average shares were 7,935 thousand versus 1,853 thousand.

Research and development expense fell to USD 3,926 thousand from USD 5,593 thousand, while selling, general and administrative expense rose to USD 3,215 thousand from USD 2,236 thousand. Total operating expenses were USD 7,141 thousand versus USD 7,829 thousand.

Total current Assets were USD 5,863 thousand versus USD 7,542 thousand, and property and equipment, net, was USD 6,694 thousand versus USD 6,866 thousand.

Other income was USD 40 thousand in the quarter versus USD 41 thousand, and the provision for income taxes was USD 2 thousand in both periods.

Six-Month Results

For the six months, net loss was USD 13,589 thousand versus USD 14,492 thousand, or USD 2.03 per share versus USD 7.91. Research and Development was USD 8,297 thousand versus USD 10,727 thousand, selling, general and administrative was USD 5,382 thousand versus USD 3,906 thousand and total operating expenses were USD 13,679 thousand versus USD 14,633 thousand.

Other income was USD 92 thousand versus USD 143 thousand. The filing attributes the quarterly rise in selling, general and administrative expense in part to higher consulting fees.

Basic and diluted weighted average shares for the six months were 6,701 thousand versus 1,831 thousand.

Product and Funding

The company is a "commercial-stage medical device company" focused on insulin pumps built on a two-part patch pump design. It received FDA clearance for the MODD1 pump in September 2024 and announced first human use of the pump delivering insulin in August 2025.

Cash and cash equivalents were USD 5,099 thousand versus USD 6,942 thousand at March 31, 2026, and total assets were USD 12,734 thousand versus USD 14,832 thousand. Net cash used in Operating Activities for the six months was USD 12,251 thousand versus USD 10,783 thousand, partly funded by USD 8,175 thousand of net proceeds from at-the-market sales of common stock. The auditor's report on the year ended March 31, 2026 expressed substantial doubt about going concern.

Accounts payable were USD 417 thousand versus USD 992 thousand, and the Equity statement shows a balance at March 31, 2026 of USD 12,959 thousand in total stockholders' equity with an accumulated Deficit of USD 112,995 thousand. Purchases of property and equipment were USD 776 thousand versus USD 1,705 thousand.

Items to Follow

Reference points include commercial rollout of the pump, selling expense relative to research spending, further at-the-market sales and the Going Concern disclosure.

The Balance Sheet figures give the starting point for these items: total current assets of USD 5,863 thousand, property and equipment of USD 6,694 thousand and a right of use asset of USD 148 thousand at September 30, 2026.